- Home
- ALLO vs GMRS Comparison
ALLO vs GMRS Comparison
Compare ALLO & GMRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.07
N/A
Current Price
$15.24
Company Overview
Basic Information| Metric | ALLO | GMRS |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 649.8M |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ALLO | GMRS |
|---|---|---|
| Price | $2.07 | $15.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $8.35 | N/A |
| AVG Volume (30 Days) | ★ 9.0M | 796.6K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $12.91 |
| 52 Week High | $4.46 | $15.00 |
Technical Indicators
Market Signals| Indicator | ALLO | GMRS |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 80.77 |
| Support Level | $1.85 | N/A |
| Resistance Level | $2.36 | N/A |
| Average True Range (ATR) | 0.13 | 0.93 |
| MACD | 0.03 | 0.16 |
| Stochastic Oscillator | 60.00 | 95.98 |
Price Performance
Historical Comparison ALLO
GMRS
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).